Perrigo Company plc Receives a Buy from Barclays

By Carrie Williams

In a report issued on December 4, Douglas Tsao from Barclays maintained a Buy rating on Perrigo Company plc (NYSE: PRGO), with a price target of $93. The company’s shares opened today at $83.54.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 2.9% and a 53.8% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, CoLucid Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Perrigo Company plc is Moderate Buy and the average price target is $94.38, representing a 13.0% upside.

In a report issued on November 28, Cantor Fitzgerald also assigned a Buy rating to the stock with a $107 price target.

Based on Perrigo Company plc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.23 billion and quarterly net profit of $44.5 million. In comparison, last year the company earned revenue of $1.26 billion and had a GAAP net loss of $1.59 billion.

Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.